| 产品描述: | Almonertinib (HS-10296) hydrochloride 是一种口服、不可逆的第三代 EGFR 酪氨酸激酶抑制剂,对 EGFR 致敏和 T790M 耐药突变具有高选择性。Almonertinib hydrochloride 对 T790M、T790M/L858R 和 T790M/Del19 表现出较强的抑制活性 (IC50 分别为 0.37、0.29 和 0.21 nM),对野生型的抑制作用较弱 (3.39 nM)。Almonertinib hydrochloride 用于非小细胞肺癌的研究。 |
| 靶点: |
EGFRT790M,0.37 nM (IC50);EGFRL858R/T790M,0.29 mM (IC50);EGFRdel19 T790M,0.214 nM (IC50);EGFR |
| 体外研究: |
Almonertinib (HS-10296) is an orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity, which canbe used to treat NSCLC. Additionaly, Almonertinib (HS-10296) could also inhibit other EGFR sensitive mutations, including G719X, del19, L858R and L861Q |
| 参考文献: |
1.Sullivan I, et al. Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line. Front Med (Lausanne). 2017 Jan 18;3:76. 2. Wu SG, et al. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018 Feb 19;17(1):38. [Content Brief]
3. 2.Yang JC, et al. Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial [published online ahead of print, 2020 Sep 9]. J Thorac Oncol. 2020;S1556-0 |
| 溶解性: |
Souble in DMSO |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.779 ml |
8.895 ml |
17.79 ml |
| 5 mM |
0.356 ml |
1.779 ml |
3.558 ml |
| 10 mM |
0.178 ml |
0.89 ml |
1.779 ml |
| 50 mM |
0.036 ml |
0.178 ml |
0.356 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |